Research in cancer immunology at the Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University (JHU) has undergone a natural progression from basic laboratory studies of the host immune response to cancer to the clinical evaluation of immune-based cancer therapies. Many of these immune-based strategies to mobilize and augment the anti-tumor immune response were founded on the discoveries made by JHU investigators. Moreover, the application of immunotherapeutic strategies as an adjunct to cancer treatment across a wide range of malignancies and therapeutic settings has expanded dramatically over the past several years. The ability to carefully and reliably quantify the human immune response is critically important to assess the impact of any immunotherapeutic strategy. While there is great diversity in the therapeutic modalities being studied, most areas, in fact, overlap strongly in their techniques and approaches to immunological analysis. Modern immunological techniques for characterizing and quantifying human immune responses are complex, and it is difficult for individual investigators to assemble all the techniques that may be most appropriate for a particular project. The Human Immunology Core Laboratory (HICL) was established in 2005 to provide SKCCC investigators the capacity to reliably monitor and quantify human immune responses using state-of-the-art immunologic assays. Thus, the specific goals of this CORE are to: 1) Provide technical expertise and conduct immunological assays to monitor and characterize the human immune responses;2) Establish standard operating procedures and quality control measures for all immunological assays;3) Communicate its expertise and availability to SKCCC investigators;4) Provide technical support to SKCCC investigators seeking to identify and develop assays specific to their research objectives, and 5) Serve as a repository for key reagents and cell lines useful for the study of human immunology. Taken together, the HICL plays an important role in monitoring human immune responses that crosses many disciplines within the SKCCC and provides for the development of new therapeutic approaches to augment the anti-tumor immune response. Lay: The Human Immunology Core Laboratory identifies different subsets of lymphocytes that participate in the immune response to cancer and assesses their function and their ability to produce inflammatory cytokines that amplify the immune response. By tracking or monitoring the immune response, the Human Immunology Core Laboratory can assist investigators assess the impact or influence of their therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-50
Application #
8559759
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
50
Fiscal Year
2013
Total Cost
$68,936
Indirect Cost
$26,384
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Johnson, Renee M; Fleming, Charles B; Cambron, Christopher et al. (2018) Race/Ethnicity Differences in Trends of Marijuana, Cigarette, and Alcohol Use Among 8th, 10th, and 12th Graders in Washington State, 2004-2016. Prev Sci :
Marrone, Kristen A; Zhou, Xian; Forde, Patrick M et al. (2018) A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. Oncologist 23:859-865
Bar-Shir, Amnon; Alon, Lina; Korrer, Michael J et al. (2018) Quantification and tracking of genetically engineered dendritic cells for studying immunotherapy. Magn Reson Med 79:1010-1019
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Dean, Lorraine T; Nicholas, Lauren Hersch (2018) Using Credit Scores to Understand Predictors and Consequences of Disease. Am J Public Health 108:1503-1505
Litvak, Anya; Batukbhai, Bhavina; Russell, Stuart D et al. (2018) Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer 124:1904-1911
Kandala, Sri Kamal; Liapi, Eleni; Whitcomb, Louis L et al. (2018) Temperature-controlled power modulation compensates for heterogeneous nanoparticle distributions: a computational optimization analysis for magnetic hyperthermia. Int J Hyperthermia :1-15
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577
Anchoori, Ravi K; Jiang, Rosie; Peng, Shiwen et al. (2018) Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer. ACS Omega 3:11917-11929

Showing the most recent 10 out of 2393 publications